This suggests that SORT1 down-regulation is a key mechanism in increasing PGRN levels by anti-SORT1 antibodies and is a promising target for PGRN boosting therapy in disorders such as FTD-PGRN or arthritis, as indicated by Pgrn KO mice phenotype. This evidence concerns the gene GRN and frontotemporal dementia.